These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

777 related items for PubMed ID: 32192286

  • 1. [Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].
    Sun D, Cheng Z, Jiang TC, Li PF, Jia LQ, Wang TT, Zheng CP, Li Y, Duo MJ.
    Zhonghua Yi Xue Za Zhi; 2020 Mar 17; 100(10):748-752. PubMed ID: 32192286
    [Abstract] [Full Text] [Related]

  • 2. Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome.
    Remuzgo-Martínez S, Atienza-Mateo B, Ocejo-Vinyals JG, Genre F, Pulito-Cueto V, Mora-Cuesta VM, Iturbe-Fernández D, Lera-Gómez L, Pérez-Fernández R, Prieto-Peña D, Irure J, Romero-Bueno F, Sanchez-Pernaute O, Alonso-Moralejo R, Nuño L, Bonilla G, Vicente-Rabaneda EF, Grafia I, Prieto-González S, Narvaez J, Trallero-Araguas E, Selva-O'Callaghan A, Spanish Biomarkers of Antisynthetase Syndrome Consortium, Spanish Biomarkers of Interstitial Lung Disease Consortium, Gualillo O, Cavagna L, Cifrián JM, Renzoni EA, Castañeda S, López-Mejías R, González-Gay MA.
    Sci Rep; 2021 Nov 19; 11(1):22574. PubMed ID: 34799647
    [Abstract] [Full Text] [Related]

  • 3. [The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases].
    Zhu C, Zhao YB, Kong LF, Li ZH, Kang J.
    Zhonghua Jie He He Hu Xi Za Zhi; 2016 Feb 19; 39(2):93-7. PubMed ID: 26879611
    [Abstract] [Full Text] [Related]

  • 4. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A, Heim X, Resseguier N, Bertin D, Gomez C, Ebbo M, Harlé JR, Kaplanski G, Rossi P, Bardin N, Granel B.
    Rheumatol Int; 2018 May 19; 38(5):813-819. PubMed ID: 29455320
    [Abstract] [Full Text] [Related]

  • 5. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.
    Lee JS, Lee EY, Ha YJ, Kang EH, Lee YJ, Song YW.
    Arthritis Res Ther; 2019 Feb 14; 21(1):58. PubMed ID: 30764869
    [Abstract] [Full Text] [Related]

  • 6. Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis.
    Hu C, Wu C, Yang E, Huang H, Xu D, Hou Y, Zhao J, Li M, Xu Z, Zeng X, Wang Q.
    Clin Rheumatol; 2019 Aug 14; 38(8):2181-2187. PubMed ID: 30888566
    [Abstract] [Full Text] [Related]

  • 7. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H, Zhao Y, Li Z, Kang J.
    Ther Adv Respir Dis; 2020 Aug 14; 14():1753466620963015. PubMed ID: 33070705
    [Abstract] [Full Text] [Related]

  • 8. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).
    Sieiro Santos C, Antolín SC, Lorenzo JC, Garay CL, Morales CM, de Miguel EB, Guerrero MR, Herránz LS, Álvarez ED.
    Semin Arthritis Rheum; 2024 Apr 14; 65():152366. PubMed ID: 38290372
    [Abstract] [Full Text] [Related]

  • 9. Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease.
    Ko UW, Cho EJ, Oh HB, Koo HJ, Do KH, Song JW.
    PLoS One; 2020 Apr 14; 15(12):e0244114. PubMed ID: 33332430
    [Abstract] [Full Text] [Related]

  • 10. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T, Otsuka M, Chiba H, Ikeda K, Mori Y, Umeda Y, Nishikiori H, Kuronuma K, Takahashi H.
    BMC Pulm Med; 2020 Jan 31; 20(1):27. PubMed ID: 32005219
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
    Xue M, Guo Z, Cai C, Sun B, Wang H.
    Respiration; 2019 Jan 31; 98(6):534-545. PubMed ID: 31665737
    [Abstract] [Full Text] [Related]

  • 12. [Single-breath and rebreathing methods for measurement of pulmonary diffusing function: a comparative study].
    Liu QX, Zheng JP, Xie YQ, Guan WJ, Jiang CY, An JY, Yu XX, Liu WT, Gao Y.
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Jul 31; 36(7):510-5. PubMed ID: 24262087
    [Abstract] [Full Text] [Related]

  • 13. Clinical Research on Prognostic Evaluation of Subjects With IPF by Peripheral Blood Biomarkers, Quantitative Imaging Characteristics and Pulmonary Function Parameters.
    Guo L, Yang Y, Liu F, Jiang C, Yang Y, Pu H, Li W, Zhong Z.
    Arch Bronconeumol (Engl Ed); 2020 Jun 31; 56(6):365-372. PubMed ID: 31740085
    [Abstract] [Full Text] [Related]

  • 14. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.
    Volkmann ER, Tashkin DP, Kuwana M, Li N, Roth MD, Charles J, Hant FN, Bogatkevich GS, Akter T, Kim G, Goldin J, Khanna D, Clements PJ, Furst DE, Elashoff RM, Silver RM, Assassi S.
    Arthritis Rheumatol; 2019 Dec 31; 71(12):2059-2067. PubMed ID: 31233287
    [Abstract] [Full Text] [Related]

  • 15. Krebs von den Lungen-6 as biomarker of the new progressive fibrotic phenotype of interstitial lung disease.
    d'Alessandro M, Conticini E, Bergantini L, Mazzei MA, Bellisai F, Selvi E, Cameli P, Frediani B, Bargagli E.
    Tissue Cell; 2024 Oct 31; 90():102516. PubMed ID: 39137538
    [Abstract] [Full Text] [Related]

  • 16. The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease.
    Ma H, Lu J, Song Y, Wang H, Yin S.
    BMC Pulm Med; 2020 Jan 08; 20(1):6. PubMed ID: 31915006
    [Abstract] [Full Text] [Related]

  • 17. Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis.
    Sokai A, Tanizawa K, Handa T, Kanatani K, Kubo T, Ikezoe K, Nakatsuka Y, Tokuda S, Oga T, Hirai T, Nagai S, Chin K, Mishima M.
    ERJ Open Res; 2017 Jul 08; 3(3):. PubMed ID: 28875146
    [Abstract] [Full Text] [Related]

  • 18. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis.
    Kennedy B, Branagan P, Moloney F, Haroon M, O'Connell OJ, O'Connor TM, O'Regan K, Harney S, Henry MT.
    Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep 14; 32(3):228-36. PubMed ID: 26422568
    [Abstract] [Full Text] [Related]

  • 19. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis.
    Akagi T, Matsumoto T, Harada T, Tanaka M, Kuraki T, Fujita M, Watanabe K.
    Respir Med; 2009 Aug 14; 103(8):1209-15. PubMed ID: 19251407
    [Abstract] [Full Text] [Related]

  • 20. The clinical value of KL-6 for predicting the occurrence and severity of connective tissue disease-associated interstitial lung disease is not affected by CTD type or treatment.
    Xing H, Liang H.
    PeerJ; 2024 Aug 14; 12():e17792. PubMed ID: 39131623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.